Inactive Instrument

Ignyta Inc Share Price

Equities

US4517311035

Biotechnology & Medical Research

Chart Ignyta Inc

Duration

Period

Style

Latest news about Ignyta Inc

Bayer : Roche takes on Loxo, Bayer in gene-defined cancer class	21/10/18	RE
Roche : to buy U.S. cancer drugmaker Ignyta for $1.7 billion	22/12/17	RE

Press releases Ignyta Inc

Ignyta : Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor	29/12/17	BU
Ignyta : Roche and Ignyta Reach Definitive Merger Agreement	22/12/17	BU
Ignyta : to Participate at the Global Mizuho Investor Conference	29/11/17	BU
Ignyta : to Present at the 29th Annual Piper Jaffray Healthcare Conference	22/11/17	BU
Ignyta : Reports Granting of Inducement Awards	16/11/17	BU

More press releases

News in other languages on Ignyta Inc

Apple : Les valeurs à suivre à Wall Street	26/12/17
Agile Therapeutics : Wall Street marque le pas avant Noël, Nike pèse	22/12/17
Citigroup : Roche rachète le laboratoire américain Ignyta 1,7 milliard de dollars	22/12/17

Managers and Directors - Ignyta Inc

Managers	Title	Age	Since
Sean Johnston CEO	Chief Executive Officer	-	07/02/18
Edward Harrington PRN	Corporate Officer/Principal	-	06/02/18
Bernard Parker SAM	Sales & Marketing	-	21/07/15

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.65%	104B
REGENERON PHARMACEUTICALS, INC.	+6.75%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-12.60%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-10.17%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+6.12%	14.39B
SAREPTA THERAPEUTICS, INC.	+35.47%	12.37B

Bio Therapeutic Drugs

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer